D
83.39
-3.51 (-4.04%)
| Previous Close | 86.90 |
| Volume | 3,574,754 |
| Price / Earnings (Forward) | 28.25 |
| Price / Sales | 7.02 |
| Price / Book | 12.63 |
| 52 Weeks Range |
| Profit Margin | 12.90% |
| Operating Margin (TTM) | 12.91% |
| Diluted EPS (TTM) | 1.33 |
| Quarterly Revenue Growth (YOY) | 12.50% |
| Quarterly Earnings Growth (YOY) | -28.00% |
| Total Debt/Equity (MRQ) | 113.97% |
| Current Ratio (MRQ) | 1.50 |
| Operating Cash Flow (TTM) | 964.10 M |
| Levered Free Cash Flow (TTM) | 509.04 M |
| Return on Assets (TTM) | 5.97% |
| Return on Equity (TTM) | 23.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | DexCom, Inc. | Mixed | Bearish |
AIStockmoo Score
-1.6
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -1.55 |
|
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 97.10% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| STERN SADIE | - | 86.68 | -2,565 | -222,334 |
| Aggregate Net Quantity | -2,565 | |||
| Aggregate Net Value ($) | -222,334 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 86.68 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| STERN SADIE | Officer | 28 Sep 2026 | Automatic sell (-) | 2,565 | 86.68 | 222,334 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |